In this July 27, 2020, file photo, nurse Kathe Olmstead prepares a shot that is part of a possible COVID-19 vaccine, developed by the National Institutes of Health and Moderna Inc., in Binghamton, N.Y. Moderna said Monday, Nov. 16, 2020, its COVID-19 shot provides strong protection against the coronavirus that's surging in the U.S. and around the world. (AP Photo/Hans Pennink, File)
For the second time this month, there's promising news from a COVID-19 vaccine candidate: Moderna said Monday its shots provide strong protection, a dash of hope against the grim backdrop of coronavirus surges in the U.S. and around the world.
Moderna said its vaccine appears to be 94.5% effective, according to preliminary data from the company’s still ongoing study. A week ago, competitor Pfizer Inc. announced its own COVID-19 vaccine appeared similarly effective — news that puts both companies on track to seek permission within weeks for emergency use in the U.S.
Dr. Stephen Hoge, Moderna’s president, welcomed the “really important milestone” but said having similar results from two different companies is what’s most reassuring.
“That should give us all hope that actually a vaccine is going to be able to stop this pandemic and hopefully get us back to our lives,” Hoge told The Associated Press.
“It won’t be Moderna alone that solves this problem. It’s going to require many vaccines” to meet the global demand, he added.
A vaccine can’t come fast enough, as virus cases topped 11 million in the U.S. over the weekend — 1 million of them recorded in just the past week. The pandemic has killed more than 1.3 million people worldwide, more than 245,000 of them in the U.S.
Still, if the Food and Drug Administration allows emergency use of Moderna’s or Pfizer’s candidates, there will be limited, rationed supplies before the end of the year. Both require people to get two shots, several weeks apart. Moderna expects to have about 20 million doses, earmarked for the U.S., by the end of 2020. Pfizer and its German partner BioNTech expect to have about 50 million doses globally by year’s end.
Moderna’s vaccine, created with the National Institutes of Health, is being studied in 30,000 volunteers who received either the real vaccination or a dummy shot. On Sunday, an independent monitoring board broke the code to examine 95 infections that were recorded starting two weeks after volunteers' second dose — and discovered all but five illnesses occurred in participants who got the placebo.
The study is continuing, and Moderna acknowledged the protection rate might change as more COVID-19 infections are detected and added to the calculations. Also, it’s too soon to know how long protection lasts. Both cautions apply to Pfizer’s vaccine as well.
But Moderna’s independent monitors reported some additional, promising tidbits: All 11 severe COVID-19 cases were among placebo recipients, and there were no significant safety concerns.
The main side effects were fatigue, muscle aches and injection-site pain after the vaccine’s second dose, at rates that Hoge characterized as more common than with flu shots but on par with others such as shingles vaccine.
Moderna shares rocketed higher on the announcement and appeared to be headed for an all-time high Monday. The Cambridge, Massachusetts, company's vaccine is among 11 candidates in late-stage testing around the world, four of them in huge studies in the U.S.
Both Moderna's shots and the Pfizer-BioNTech candidate are so-called mRNA vaccines, a brand-new technology. They aren’t made with the coronavirus itself, meaning there’s no chance anyone could catch it from the shots. Instead, the vaccine contains a piece of genetic code that trains the immune system to recognize the spiked protein on the surface of the virus.
The strong results were a surprise. Scientists have warned for months that any COVID-19 shot may be only as good as flu vaccines, which are about 50% effective.
Another steep challenge: distributing doses that must be kept very cold. Both the Moderna and Pfizer shots are frozen but at different temperatures. Moderna announced Monday that once thawed, its doses can last longer in a refrigerator than initially thought, up to 30 days. Pfizer's shots require long-term storage at ultra-cold temperatures.
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content.
Carlo and Baker cover the latest developments with the Omicron variant, and break down what we know and what we still don't. Plus, a relatively tame Black Friday, and more.
Dr. Amesh Adalja, an infectious disease specialist and senior scholar at Johns Hopkins Center for Health Security, joined Cheddar to discuss the nations joining in on a travel ban against several African nations after South Africa reported the emergence of the omicron variant of COVID-19 currently worrying health experts. Adalja also added his own voice to the World Health Organization's objection to the travel ban at this time. "When you do a travel ban, you basically waste a lot of resources implementing the travel ban, you give people a false sense of security when the virus is likely already outside of the area of the travel ban, and then you punish countries like South Africa." He noted that South Africa should be praised for its transparency and not punished with restrictions, an act he thinks will lead to a chilling effect among other nations sharing data freely.
Blue Origin is gearing up for its next launch, set to blast off on December 9th. Michael Strahan is one of the six crew members who will snag a seat on the the New Shepard rocket. Jim Cantrell, CEO and co-founder at Phantom Space, joins Cheddar News to discuss.
Donald Pettey, Program Manager for Strategic Initiatives for MassDOT, and Mohammed Siddiqui, Vice President of Public Relations at Ko-Solar, join Cheddar Climate, where they discuss their plan to test highway barriers that absorb sound and solar energy, with construction expected to begin in the first half of 2022.
Over 100 world leaders signed on to a pledge at the United Nations COP26 climate meeting with the aim of ending and reversing deforestation by 2030. Leaders agreed to conserve forests and ecosystems, support developing countries on deforestation prevention, and more. Rod Taylor, Global Forests Director at the World Resources Institute, joins Cheddar Climate to discuss the pledge, whether it will have a significant impact, whether 2030 is a suitable deadline, and how we can verify if forests are actually being protected.
President Joe Biden's "Build Back Better" bill could mean cheaper electric bicycles and scooters as the nation attempts to shift away from gas-powered cars. Noa Banayan, the director of federal affairs at PeopleForBikes, joined Cheddar's "Closing Bell" to provide some background on the E-Bike Act included in Biden's reconciliation bill that would provide tax credits for qualified purchases. "We want to make sure, from the bike industry's perspective, that this is a technology and a product that is available to the majority of Americans who want to lower their carbon footprint and get around town faster and do everything that they would normally do in a short car trip but by bike, because it's healthier, it's fast, it's efficient, you're not in traffic," she said.
It's being called the next big trend in crypto. A decentralized autonomous organization, or DAO, is an internet community of different types of groups and businesses. The purpose is to allow people to commit funds to a specific cause in a safe way. Now, one social platform is creating a do-it-yourself kit for those who want to step into the space. Upstream Collective just launched the beta mode of its platform with the goal of putting all facets of running a DAO in one place. Alex Taub, co-founder and CEO of Upstream, joins Cheddar News to discuss.
A NASA spacecraft that will deliberately crash into an asteroid is preparing to launch this week. The goal of the DART mission, or the Double Asteroid Redirection Test, is to hit the smaller of the two asteroids, Dimorphos, with the spacecraft at about 15,000 miles per hour and see how the impact changes the asteroid’s trajectory. Joey Roulette, space reporter at The New York Times, joins Cheddar News to talk more about it.
NFL Hall of Famer and "Good Morning America" host Michael Strahan will be able to add space travel to his list of accomplishments as he prepares to launch into orbit with the next Blue Origin mission.
